

See patients' complete glycemic profile. Help them achieve better outcomes.

Lower A1c*1 with an affordable⁺ non-medication approach for your Type 2 diabetes patients

FreeStyle Libre 3 system

1.6% >

Common orals and injectables 0.4-1.3% 🛠 GLP1-RA 0.5-0.6% 🛠 SGLT2-I 0.5% 🛠 DPP4-I A1c Reduction^{‡2}

The data above is not from a head-to-head study.

Now You Know

Abbott life. to the fullest.

The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre 3 app requires registration with LibreView.

At this time, the FreeStyle Libre 3 system is not currently eligible for Medicare reimbursement, and Medicaid eligibility may vary by state.

*In type 2 non-insulin treated patients with mean baseline AIc levels of 10.1%. **†**Based on a comparison of list prices of the FreeStyle Libre 2 system versus competitors' CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any. **‡**Change in A1c level with add-on therapy in patients receiving metformin. The mean baseline A1c level was 8.3%.

1. Wright, E. Diabetes Spectrum (2021): https://doi.org/10.2337/ds20-0069. 2. Tsapas, A. Annals of Internal Medicine (2020): https://doi.org/10.7326/M20-0864. See reverse for Important Safety Information.

FreeStyle Libre 3 system provides easy visibility to hidden problems¹



Introduce your patients to Breakthrough CGM Technology



≫Easy

Easy to use^{*2} and easy to apply³ with a 1-piece applicator



Discretion

Smallest³, thinnest[†] sensor; no fingersticks[‡]



» Performance

Always on[§]-patients can view their glucose with a quick glance at their smartphones^{II}

Simply prescribe the most affordable¹³ CGM today



For illustrative purposes only. No actual patient data.

The FreeStyle Libre 3 system is indicated for use in people with diabetes age 4 and older.

At this time, FreeStyle Libre 3 is not currently eligible for Medicare reimbursement, and Medicaid eligibility may vary by state.

*Data from this study was collected with the outside US version of the FreeStyle Libre 14 day system. FreeStyle Libre 3 has the same features as FreeStyle Libre 14 day system with real-time glucose alarms. Therefore the study data is applicable to both products. †Among patient-applied sensors. ‡Fingersticks are required if your glucose alarms and readings do not match symptoms or when you see Check Blood Glucose symbol in the first twelve hours. **\$** 60-minute warm-up required when starting the sensor. **||** The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our website for more information about device compatibility before using the app. Use of the FreeStyle Libre 3 app requires registration with LibreView. **\$**Based on a comparison of list prices of the FreeStyle Libre 3 system versus competitors' CGM systems. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any. Does not include Medicare, Medicaid, and uninsured patients.

1. Unger, J. Postgraduate Medicine (2020): https://doi.org/10.1080/00325481.2020.1744393. 2. Haak, T. Diabetes Therapy (2017): https://doi.org/10.1007/s13300-016-0223-6. 3. Data on file. Abbott Diabetes Care.

Important Safety Information

Failure to use FreeStyle Libre 3 system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or https://www.FreeStyle.abbott/us-en/safety-information.html for safety info.

The circular shape of the sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners. ©2022 Abbott. ADC-62610 v1.0 09/22